Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Changes in second-line lymphoma treatment

Alison Moskowitz • 2 Jun 2019
ASCO 2019
Lymphoma Rituximab

Alison Moskowitz, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the standard approach to relapsed/refractory lymphoma and the increased use of novel agents such as rituximab and checkpoint inhibitors in second-line therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Alison Moskowitz

A study of pembrolizumab maintenance as an alternative to autoSCT in R/R Hodgkin lymphoma 3:20
A study of pembrolizumab maintenance as an alternative to autoSCT in R/R Hodgkin lymphoma
Alison Moskowitz • 9 Dec 2024
Acimtamig with off-the-shelf allogeneic NK-cells in R/R cHL 1:44
Acimtamig with off-the-shelf allogeneic NK-cells in R/R cHL
Alison Moskowitz • 9 Dec 2024
A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma 1:52
A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma
Alison Moskowitz • 9 Dec 2024
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma 2:50
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021

Related Videos

Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL 2:11
Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL
Reid Merryman • 8 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals